1 |
GBD Tuberculosis Collaborators. The global burden of tuberculosis: results from the Global Burden of Disease Study 2015. Lancet Infect Dis. 2018;18:261-284. https://doi.org/10.1016/S1473-3099(17)30703-X
DOI
|
2 |
Korea Centers for Disease Control and Prevention. Korean guidelines for tuberculosis (4th edition). Seoul: Korea Centers for Disease Control and Prevention; 2020. p16-59.
|
3 |
Pablos-Mendez A, Raviglione MC, Laszlo A, Binkin N, Rieder HL, Bustreo F, et al. Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization-International Union against tuberculosis and lung disease working group on anti-tuberculosis drug resistance surveillance. N Engl J Med. 1998;338:1641-1649. http://doi.org/10.1056/NEJM199806043382301
DOI
|
4 |
Kim DH, Kim HJ, Park SK, Kong SJ, Kim YS, Kim TH. et al. Treatment outcomes and long-term survival in patients with extensively drug-resistant tuberculosis. Am J Respir Crit Care Med. 2008;178:1075-1082. https://doi.org/10.1164/rccm.200801-132OC
DOI
|
5 |
World Health Organizaton. Guidelines for the programmatic management of drug-resistant tuberulosis. Emergency update 2008. Geneva.World Health Organization; 2008.
|
6 |
Joint Committee for the Development of Korean Guideline for Tuberculosis; Korean Centers for Disease Control and Prevention. Korean guidelines for tuberculosis. 1st ed. Cheongwon: Korea Centers for Disease Control and Prevention; 2011.
|
7 |
Van Deun A, Maug AK, Salim MA, Das PK, Sarker MR, Daru P, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2010;182:684-692. https://doi.org/10.1164/rccm.201001-0077OC
DOI
|
8 |
Kim BJ, Lee IH, Lee DH, Bai GH, Kong SJ, Lee SH, et al. The Current Status of Multidrug-resistant Tuberculosis in Korea. Tuberc Respir Dis. 2006;60:404-411. https://doi.org/10.4046/trd.2006.60.4.404
DOI
|
9 |
World Health Organization. Global tuberculosis report 2018. Geneva. World Health Organization; 2018.
|
10 |
Centers for Disease Control and Prevention (CDC). Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs--worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep. 2006;55:301-305. https://doi.org/10.1037/e566482006-002
DOI
|
11 |
Velayati AA, Masjedi MR, Farnia P, Tabarsi P, Ghanavi J, Ziazarifi AH, et al. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in iran. Chest. 2009;136:420-425. https://doi.org/10.1378/chest.08-2427
DOI
|
12 |
Espinal MA, Laszlo A, Simonsen L, Boulahbal F, Kim SJ, Reniero A, et al. Global trends in resistance to antituberculosis drugs. World Health Organization-International union against tuberculosis and lung disease working group on anti-tuberculosis drug resistance surveillance. N Engl J Med. 2001;344:1294-1303. http://doi.org/10.1056/NEJM200104263441706
DOI
|
13 |
Mitchison DA. Drug resistance in tuberculosis. Eur Respir J. 2005;25:376-379. https://doi.org/10.1183/09031936.05.00075704
DOI
|
14 |
World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis. Geneva. World Health Organization; 2016.
|
15 |
Korea Centers for Disease Control and Prevention. Annual report on the notified tuberculosis patients in Korea 2019. Seoul: Korea Centers for Disease Control and Prevention; 2020. p35-41.
|
16 |
Lee KT, Chong MS. The patterns of acquiring anti-mycobacterial drug resistance by susceptible strains of Mycobacterium tuberculosis. Korean J Clin Lab Sci. 2021;53:137-142. https://doi.org/10.15324/kjcls.2021.53.2.137
DOI
|
17 |
Son EJ, Jeon DS. Current situation of tuberculosis and national strategic plan for tuberculosis control in Korea. J Korean Med Assoc. 2021;64:316-323. http://doi.org/10.5124/jkma.2021.64.4.316
DOI
|
18 |
Kang YA. Diagnosis and treatment of multidrug-resistant tuberculosis. J Korean Med Assoc. 2014;57:27-33. http://doi.org/10.5124/jkma.2014.57.1.27
DOI
|